nach oben

Erschienen in:

01.05.2015 | Original Article

Keratin 17 is co-expressed with 14-3-3 sigma in oral carcinoma in situ and squamous cell carcinoma and modulates cell proliferation and size but not cell migration

verfasst von: Toshihiko Mikami, Satoshi Maruyama, Tatsuya Abé, Takanori Kobayashi, Manabu Yamazaki, Akinori Funayama, Susumu Shingaki, Tadaharu Kobayashi, Cheng Jun, Takashi Saku

Erschienen in: Virchows Archiv | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

Expression of keratin (K) 13 is replaced with that of K17 when squamous cells of the oral mucosa transform from normal and dysplastic epithelia to carcinoma in situ (CIS) and squamous cell carcinoma (SCC). Since 14-3-3 sigma is functionally associated with K17, we examined possible relationships between expression of K17 and 14-3-3 sigma in oral CIS and SCC tissues by immunohistochemistry. We furthermore examined whether or not K17 expression or knockdown by small interfering RNA (siRNA) modulates the behavior of SCC cells in culture in terms of cell proliferation and migration. In tissue specimens of oral SCC and CIS, the pattern of cytoplasmic expression of 14-3-3 sigma and K17 was similar but neither was expressed in normal or dysplastic epithelia. Both proteins were demonstrated in the cytoplasm of control oral SCC ZK-1 cells, but expression of 14-3-3 sigma changed from cytoplasmic to nuclear upon knockdown of K17. In carcinoma cells, therefore, cytoplasmic localization of 14-3-3 sigma seems to accompany expression of K17. In K17-knockdown cells, proliferation was significantly suppressed at 4 days after seeding. In addition, the cell size of K17-knockdown cells was significantly smaller than that of control cells; as a result of which in the migration experiments, we found delayed closure of scratch wounds but migration as such was not affected. We conclude that K17 expression promotes SCC cell growth and cell size but does not affect cell migration. K17 expression is accompanied by cytoplasmic expression of 14-3-3 sigma, indicative of their functional relationship.

Nur mit Berechtigung zugänglich

Kobayashi T, Maruyama S, Cheng J, Ida-Yonemochi H, Yagi M, Takagi R, Saku T (2010) Histopathological varieties of oral carcinoma in situ: diagnosis aided by immunohistochemistry dealing with the second basal cell layer as the proliferating center of oral mucosal epithelia. Pathol Int 60:156–166CrossRefPubMed

Funayama A, Cheng J, Maruyama S, Yamazaki M, Kobayashi T, Syafriadi M, Kundu S, Shingaki S, Saito C, Saku T (2011) Enhanced expression of podoplanin in oral carcinomas in situ and squamous cell carcinomas. Pathobiology 78:171–180CrossRefPubMed

Mikami T, Cheng J, Maruyama S, Kobayashi T, Funayama A, Yamazaki M, Adeola HA, Wu L, Shingaki S, Saito C, Saku T (2011) Emergence of keratin 17 vs. loss of keratin 13: their reciprocal immunohistochemical profiles in oral carcinoma in situ. Oral Oncol 47:497–503CrossRefPubMed

Kobayashi T, Maruyama S, Abé T, Cheng J, Takagi R, Saito C, Saku T (2012) Keratin-10-positive orthokeratotic dysplasia: a new leukoplakia-type precancerous entity of the oral mucosa. Histopathology 61:910–920CrossRefPubMed

Funayama A, Maruyama S, Yamazaki M, Al-Eryani K, Shingaki S, Saito C, Cheng J, Saku T (2012) Intraepithelially entrapped blood vessels in oral carcinoma in-situ. Virchows Arch 460:473–480CrossRefPubMed

Ida-Yonemochi H, Maruyama S, Kobayashi T, Yamazaki M, Cheng J, Saku T (2012) Loss of keratin 13 in oral carcinoma in situ: a comparative study of protein and gene expression levels using paraffin sections. Mod Pathol 25:784–794CrossRefPubMed

Ikarashi T, Ida-Yonemochi H, Ohshiro K, Cheng J, Saku T (2004) Intraepithelial expression of perlecan, a basement membrane-type heparan sulfate proteoglycan reflects dysplastic changes of the oral mucosal epithelium. J Oral Pathol Med 33:87–95CrossRefPubMed

Tilakaratne WM, Kobayashi T, Ida-Yonemochi H, Swelam W, Yamazaki M, Mikami T, Alvarado CG, Shahidul AM, Maruyama S, Cheng J, Saku T (2009) Matrix metalloproteinase 7 and perlecan in oral epithelial dysplasia and carcinoma in situ: an aid for histopathologic recognition of their cell proliferation centers. J Oral Pathol Med 38:348–355CrossRefPubMed

Metwaly H, Maruyama S, Yamazaki M, Tsuneki M, Abé T, Jen KY, Cheng J, Saku T (2012) Parenchymal-stromal switching for extracellular matrix production on invasion of oral squamous cell carcinoma. Hum Pathol 43:1973–1981CrossRefPubMed

10.

Alvarado CG, Maruyama S, Cheng J, Ida-Yonemochi H, Kobayashi T, Yamazaki M, Takagi R, Saku T (2011) Nuclear translocation of beta-catenin synchronized with loss of E-cadherin in oral epithelial dysplasia with a characteristic two-phase appearance. Histopathology 59:283–291PubMed

11.

Troyanovsky SM, Guelstein VI, Tchipysheva TA, Krutovskikh VA, Bannikov GA (1989) Patterns of expression of keratin 17 in human epithelia: dependency on cell position. J Cell Sci 93:419–426PubMed

12.

Kim S, Wong P, Coulombe PA (2006) A keratin cytoskeletal protein regulates protein synthesis and epithelial cell growth. Nature 441:362–365CrossRefPubMed

13.

Maruyama S, Cheng J, Yamazaki M, Zhou XJ, Zhang ZY, He RG, Saku T (2010) Metastasis-associated genes in salivary adenoid cystic carcinoma and oral squamous cell carcinoma: a differential DNA chip analysis between metastatic and non-metastatic cell systems. Cancer Genet Cytogenet 195:14–22CrossRef

14.

Syafriadi M, Cheng J, Jen KY, Ida-Yonemochi H, Suzuki M, Saku T (2005) Two-phase appearance of oral epithelial dysplasia resulting from focal proliferation of parabasal cells and apoptosis of prickle cells. J Oral Pathol Med 34:140–149CrossRefPubMed

15.

Smith FJ, Jonkman MF, van Goor H, Coleman CM, Covello SP, Uitto J, McLean WH (1998) A mutation in human keratin K6b produces a phenocopy of the K17 disorder pachyonychia congenita type 2. Hum Mol Genet 7:1143–1148CrossRefPubMed

16.

Troyanovsky SM, Leube RE, Franke WW (1992) Characterization of the human gene encoding cytokeratin 17 and its expression pattern. Eur J Cell Biol 59:127–137PubMed

17.

McGowan KM, Coulombe PA (1998) Onset of keratin 17 expression coincides with the definition of major epithelial lineages during skin development. J Cell Biol 143:469–486CrossRefPubMedCentralPubMed

18.

Freedberg IM, Tomic-Canic M, Komine M, Blumenberg M (2001) Keratins and the keratinocyte activation cycle. J Investig Dermatol 116:633–640CrossRefPubMed

19.

Kozma SC, Thomas G (2002) Regulation of cell size in growth, development and human disease: PI3K, PKB and S6K. Bioessays 24:65–71CrossRefPubMed

20.

Bertram PG, Zeng C, Thorson J, Shaw AS, Zheng XF (1998) The 14-3-3 proteins positively regulate rapamycin-sensitive signaling. Curr Biol 8:1259–1267CrossRefPubMed

21.

Yang HY, Wen YY, Chen CH, Lozano G, Lee MH (2003) 14-3-3 sigma positively regulates p53 and suppresses tumor growth. Mol Cell Biol 23:7096–7107CrossRefPubMedCentralPubMed

22.

Chan TA, Hwang PM, Hermeking H, Kinzler KW, Vogelstein B (2000) Cooperative effects of genes controlling the G(2)/M checkpoint. Genes Dev 14:1584–1588PubMedCentralPubMed

23.

Strimpakos AS, Karapanagiotou EM, Saif MW, Syrigos KN (2009) The role of mTOR in the management of solid tumors: an overview. Cancer Treat Rev 35:148–159CrossRefPubMed

24.

Janus A, Robak T, Smolewski P (2005) The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy. Cell Mol Biol Lett 10:479–498PubMed

25.

Asnaghi L, Bruno P, Priulla M, Nicolin A (2004) mTOR: a protein kinase switching between life and death. Pharmacol Res 50:545–549CrossRefPubMed

26.

Xu G, Zhang W, Bertram P, Zheng XF, McLeod H (2004) Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. Int J Oncol 24:893–900PubMed

27.

Hay N, Sonenberg N (2004) Upstream and downstream of mTOR. Genes Dev 18:1926–1945CrossRefPubMed

28.

Hayashi E, Kuramitsu Y, Fujimoto M, Zhang X, Tanaka T, Uchida K, Fukuda T, Furumoto H, Ueyama Y, Nakamura K (2009) Proteomic profiling of differential display analysis for human oral squamous cell carcinoma: 14-3-3 σ protein is upregulated in human oral squamous cell carcinoma and dependent on the differentiation level. Proteomics Clin Appl 3:1338–1347CrossRefPubMed

29.

Kirschner M, Montazem A, Hilaire HS, Radu A (2006) Long-term culture of human gingival keratinocyte progenitor cells by down-regulation of 14-3-3 sigma. Stem Cells Dev 15:556–565CrossRefPubMed

30.

Takahashi Y, Nishikawa M, Takakura Y (2006) Suppression of tumor growth by intratumoral injection of short hairpin RNA-expressing plasmid DNA targeting beta-catenin or hypoxia-inducible factor 1alpha. J Control Release 116:90–95CrossRefPubMed

31.

Wang Z, Rao DD, Senzer N, Nemunaitis J (2011) RNA interference and cancer therapy. Pharm Res 28:2983–2995CrossRefPubMed

32.

Liu X, Sempere LF, Ouyang H, Memoli VA, Andrew AS, Luo Y, Demidenko E, Korc M, Shi W, Preis M, Dragnev KH, Li H, Direnzo J, Bak M, Freemantle SJ, Kauppinen S, Dmitrovsky E (2010) MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest 120:1298–1309CrossRefPubMedCentralPubMed

33.

Santel A, Aleku M, Röder N, Möpert K, Durieux B, Janke O, Keil O, Endruschat J, Dames S, Lange C, Eisermann M, Löffler K, Fechtner M, Fisch G, Vank C, Schaeper U, Giese K, Kaufmann J (2010) Atu027 prevents pulmonary metastasis in experimental and spontaneous mouse metastasis models. Clin Cancer Res 16:5469–5480CrossRefPubMed

34.

Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A (2010) Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464:1067–1070CrossRefPubMedCentralPubMed

35.

Patnaik A, Chiorean EG, Tolcher A, Papadopoulos K, Beeram M, Kee D, Waddell M, Gilles E, Buchbinder A (2009) EZN-2968, a novel hypoxia-inducible factor-1 alpha (HIF-1 alpha) messenger ribonucleic acid (mRNA) antagonist: results of a phase I, pharmacokinetic (PK), dose-escalation study of daily administration in patients (pts) with advanced malignancies. J Clin Oncol 27:2564

36.

Senzer N, Barve M, Kuhn J, Melnyk A, Beitsch P, Lazar M, Lifshitz S, Magee M, Oh J, Mill SW, Bedell C, Higgs C, Kumar P, Yu Y, Norvell F, Phalon C, Taquet N, Rao DD, Wang Z, Jay CM, Pappen BO, Wallraven G, Brunicardi FC, Shanahan DM, Maples PB, Nemunaitis J (2012) Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer. Mol Ther 20:679–686CrossRefPubMedCentralPubMed

37.

Wei KJ, Zhang L, Yang X, Zhong LP, Zhou XJ, Pan HY, Li J, Chen WT, Zhang ZY (2009) Overexpression of cytokeratin 17 protein in oral squamous cell carcinoma in vitro and in vivo. Oral Dis 15:111–117CrossRefPubMed

38.

Sarbia M, Fritze F, Geddert H, von Weyhern C, Rosenberg R, Gellert K (2007) Differentiation between pancreaticobiliary and upper gastrointestinal adenocarcinomas: is analysis of cytokeratin 17 expression helpful? Am J Clin Pathol 128:255–259CrossRefPubMed

39.

van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J, Torhorst J, Sauter G, Zuber M, Köchli OR, Mross F, Dieterich H, Seitz R, Ross D, Botstein D, Brown P (2002) Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 161:1991–1996CrossRefPubMedCentralPubMed

40.

Yoshikawa K, Katagata Y, Kondo S (1998) Biochemical and immunohistochemical analyses of keratin expression in basal cell carcinoma. J Dermatol Sci 17:15–23CrossRefPubMed

41.

Ikeda K, Tate G, Suzuki T, Mitsuya T (2008) Coordinate expression of cytokeratin 8 and cytokeratin 17 immunohistochemical staining in cervical intraepithelial neoplasia and cervical squamous cell carcinoma: an immunohistochemical analysis and review of the literature. Gynecol Oncol 108:598–602CrossRefPubMed

42.

Carrilho C (2004) Keratins 8, 10, 13, and 17 are useful markers in the diagnosis of human cervix carcinomas. Hum Pathol 35:546–551CrossRefPubMed

43.

Cohen-Kerem R, Madah W, Sabo E, Rahat MA, Greenberg E, Elmalah I (2004) Cytokeratin-17 as a potential marker for squamous cell carcinoma of the larynx. Ann Otol Rhinol Laryngol 113:821–827CrossRefPubMed

44.

Lyda MH, Weiss LM (2000) Immunoreactivity for epithelial and neuroendocrine antibodies are useful in the differential diagnosis of lung carcinomas. Hum Pathol 31:980–987CrossRefPubMed

45.

Saito M, Kobayashi T, Takagi R, Saku T (2012) Clinicopathological distinction of two categories of oral squamous cell carcinoma of the tongue: de novo vs. sequential types. Oral Med Pathol 16:81–88CrossRef

46.

Shegokar R, Al Shaal L, Mishra PR (2011) SiRNA delivery: challenges and role of carrier systems. Pharmazie 66:313–318PubMed

47.

Dominska M, Dykxhoorn DM (2010) Breaking down the barriers: siRNA delivery and endosome escape. J Cell Sci 123:1183–1189CrossRefPubMed

48.

Takanashi M, Oikawa K, Sudo K, Tanaka M, Fujita K, Ishikawa A, Nakae S, Kaspar RL, Matsuzaki M, Kudo M, Kuroda M (2009) Therapeutic silencing of an endogenous gene by siRNA cream in an arthritis model mouse. Gene Ther 16:982–989CrossRefPubMed

Titel: Keratin 17 is co-expressed with 14-3-3 sigma in oral carcinoma in situ and squamous cell carcinoma and modulates cell proliferation and size but not cell migration
verfasst von: Toshihiko Mikami
Satoshi Maruyama
Tatsuya Abé
Takanori Kobayashi
Manabu Yamazaki
Akinori Funayama
Susumu Shingaki
Tadaharu Kobayashi
Cheng Jun
Takashi Saku
Publikationsdatum: 01.05.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Virchows Archiv / Ausgabe 5/2015
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-015-1735-6

Springer Medizin

Keratin 17 is co-expressed with 14-3-3 sigma in oral carcinoma in situ and squamous cell carcinoma and modulates cell proliferation and size but not cell migration

Abstract

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2015

Aurora B expression and histone variant H1.4S27 phosphorylation are no longer coordinated during metaphase in aneuploid colorectal carcinomas

Tumor budding in colorectal cancer revisited: results of a multicenter interobserver study

Diagnosing cytomegalovirus in patients with inflammatory bowel disease—by immunohistochemistry or polymerase chain reaction?

In stage II/III lymph node-positive breast cancer patients less than 55 years of age, keratin 8 expression in lymph node metastases but not in the primary tumour is an indicator of better survival

Immunohistochemical distinction of metastases of renal cell carcinoma to the adrenal from primary adrenal nodules, including oncocytic tumor

Expression of proteins associated with hypoxia and Wnt pathway activation is of prognostic significance in hepatocellular carcinoma

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie